AVH Stock Overview
AVITA Medical, Inc. junto con sus filiales, opera como empresa de medicina regenerativa en Estados Unidos e internacionalmente.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AVH from our risk checks.
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.66 |
| 52 Week High | US$6.27 |
| 52 Week Low | US$2.88 |
| Beta | 1.38 |
| 1 Month Change | -14.18% |
| 3 Month Change | 21.35% |
| 1 Year Change | 7.13% |
| 3 Year Change | -13.70% |
| 5 Year Change | -41.01% |
| Change since IPO | -91.37% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About AVITA Medical's (ASX:AVH) Cash Burn Situation
Sep 22
We're Interested To See How AVITA Medical (ASX:AVH) Uses Its Cash Hoard To Grow
Jun 02Here's Why We're Not At All Concerned With AVITA Medical's (ASX:AVH) Cash Burn Situation
Jan 11Companies Like AVITA Medical (ASX:AVH) Are In A Position To Invest In Growth
Feb 07AVITA Medical's (ASX:AVH) Wonderful 304% Share Price Increase Shows How Capitalism Can Build Wealth
Dec 17Shareholder Returns
| AVH | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -5.9% | -1.7% | -1.0% |
| 1Y | 7.1% | -5.3% | 9.1% |
Rentabilidad frente al sector: AVH superó al sector Australian Biotechs , que obtuvo un rendimiento del -4% el año pasado.
Rentabilidad vs. Mercado: AVH obtuvo unos resultados inferiores a los del mercado Australian, que fue del 9.1% el año pasado.
Price Volatility
| AVH volatility | |
|---|---|
| AVH Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 3.3% |
Precio estable de las acciones: AVH no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de AVH (9%) se ha mantenido estable durante el año pasado.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 207 | Jim Corbett | https://www.avitamedical.com |
AVITA Medical, Inc. junto con sus filiales, opera como empresa de medicina regenerativa en Estados Unidos e internacionalmente. El principal producto de la empresa es el sistema RECELL, un dispositivo de recolección de células utilizado para el tratamiento de heridas por quemaduras térmicas, defectos cutáneos de espesor total y repigmentación de lesiones de vitíligo despigmentadas estables. Desarrolla RECELL GO para controlar el proceso manual de desagregación, filtración y tiempo de remojo.
AVITA Medical, Inc. Fundamentals Summary
| AVH fundamental statistics | |
|---|---|
| Market cap | AU$590.56m |
| Earnings (TTM) | -AU$53.52m |
| Revenue (TTM) | AU$75.85m |
7.8x
P/S Ratio-11.0x
P/E RatioIs AVH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVH income statement (TTM) | |
|---|---|
| Revenue | US$50.14m |
| Cost of Revenue | US$7.78m |
| Gross Profit | US$42.36m |
| Other Expenses | US$77.74m |
| Earnings | -US$35.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 84.48% |
| Net Profit Margin | -70.56% |
| Debt/Equity Ratio | 81.2% |
How did AVH perform over the long term?
See historical performance and comparison